Across TCGA pan-cancer cohorts, JAG2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JAG2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher JAG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated JAG2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, LIHC, and SKCM are the cancer types where JAG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.153	0.663	.004	18	view →
LIHC	DFS	Median	All	0.096	0.553	.030	3	view →
SKCM	DFS	Median	All	0.803	0.202	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: JAG2 tumor-vs-normal RNA expression · all JAG2 data types